CVS Health’s CVS 2026 revenues are now projected to be at least $414 billion, up from the earlier projection of at least $405 billion. The company also boosted adjusted earnings guidance to $7.90-$8.10 from $7.30-$7.50. However, it faces several challenges that could weigh on 2026 financial outlook.
In line with this, the company is exposed to reimbursement pressure across its government, retail pharmacy and PBM businesses. In second-quarter 2026, Pharmacy & Consumer Wellness segment’s growth was offset by regulatory-related price reductions, generic introductions and pharmacy reimbursement pressure.
The Health Services segment also absorbed pharmacy client price improvements, limiting revenues and adjusted operating income gains. CVS also views the 2027 Medicare Advantage payment update as insufficient to fully offset underlying medical cost trends. These factors require continued focus on purchasing economics, pricing discipline and contract structures to protect margins.
Additionally, the company continues to factor potential macro headwinds into its 2026 outlook. Inflation, tariffs, interest rates, unemployment and supply-chain disruption can affect costs, consumer behavior and cash flow across the enterprise. Front-store demand remains sensitive to shifts toward value, grocery and digital retailers, with same-store front-store sales rising just 1% year over year in the second quarter. Weaker consumer spending could further limit front-store growth.
Peer Update
Align Technology ALGN continues to operate in an uneven demand environment because orthodontic treatment and dental capital equipment purchases are sensitive to consumer and practice spending. The capital equipment market remained weak as higher interest rates and economic uncertainty affected scanner purchasing decisions. This contributed to a 10.8% year-over-year decline in Systems and Services revenues during the second quarter.
Regulatory developments add another cost consideration. In July 2026, the U.K. Upper Tribunal overturned the prior VAT-exemption ruling for clear aligners. Align recorded an estimated $37.5 million liability, including interest, and will begin applying 20% VAT to applicable U.K. Invisalign aligners and Vivera retainers from Sept. 7, 2026, without changing list prices. The company plans to appeal the decision, adding uncertainty around the ultimate financial impact.
Cardinal Health CAH still depends on large distribution relationships, making contract renewals and customer mix important to revenue scale and pricing. The fiscal 2025 OptumRx expiration demonstrated how a major contract change can alter reported growth and distribution volumes.
Global Medical Products and Distribution (“GMPD”) remains exposed to tariffs, fuel and commodity costs, and geopolitical disruption across its global sourcing network. CAH also stated that a prolonged conflict in Iran could move GMPD toward the lower end of its $200 million to $220 million segment profit range. The timing and magnitude of future tariff offsets remain uncertain, so trade policy and sourcing costs can still create volatility in GMPD earnings even as the improvement plan advances.
CVS’ Price Performance, Valuation and Estimates
Over the past year, CVS Health shares have risen 18.3% compared with the industry’s 13.2% growth.
Image Source: Zacks Investment Research
CVS shares are trading at a forward one-year price-to-sales ratio of 0.27, lower than the industry average of 0.53. The stock has a Value Score of A.
Image Source: Zacks Investment Research
The consensus estimate for the company’s 2026 earnings has been showing a bearish trend.
Image Source: Zacks Investment Research
CVS currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CVS Health Corporation (CVS): Free Stock Analysis Report
Align Technology, Inc. (ALGN): Free Stock Analysis Report
Cardinal Health, Inc. (CAH): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).